As of Jun 18
| -0.08 / -0.61%|
The 6 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 12.50, with a high estimate of 15.00 and a low estimate of 11.00. The median estimate represents a -3.85% decrease from the last price of 13.00.
The current consensus among 7 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.